JP2004513151A5 - - Google Patents

Download PDF

Info

Publication number
JP2004513151A5
JP2004513151A5 JP2002540751A JP2002540751A JP2004513151A5 JP 2004513151 A5 JP2004513151 A5 JP 2004513151A5 JP 2002540751 A JP2002540751 A JP 2002540751A JP 2002540751 A JP2002540751 A JP 2002540751A JP 2004513151 A5 JP2004513151 A5 JP 2004513151A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002540751A
Other versions
JP2004513151A (ja
JP4167061B2 (ja
Filing date
Publication date
Priority claimed from IT2000RM000578A external-priority patent/IT1317930B1/it
Application filed filed Critical
Publication of JP2004513151A publication Critical patent/JP2004513151A/ja
Publication of JP2004513151A5 publication Critical patent/JP2004513151A5/ja
Application granted granted Critical
Publication of JP4167061B2 publication Critical patent/JP4167061B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002540751A 2000-11-08 2001-11-08 成長因子ｆｇｆ−２の活性化の変化によって起こる疾患の治療のための長いペントラキシンｐｔｘ３の使用 Expired - Fee Related JP4167061B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000RM000578A IT1317930B1 (it) 2000-11-08 2000-11-08 Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
PCT/IT2001/000563 WO2002038169A1 (en) 2000-11-08 2001-11-08 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2

Publications (3)

Publication Number Publication Date
JP2004513151A JP2004513151A (ja) 2004-04-30
JP2004513151A5 true JP2004513151A5 (ja) 2005-12-22
JP4167061B2 JP4167061B2 (ja) 2008-10-15

Family

ID=11454983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002540751A Expired - Fee Related JP4167061B2 (ja) 2000-11-08 2001-11-08 成長因子ｆｇｆ−２の活性化の変化によって起こる疾患の治療のための長いペントラキシンｐｔｘ３の使用

Country Status (22)

Country Link
US (1) US7858577B2 (ja)
EP (1) EP1331940B1 (ja)
JP (1) JP4167061B2 (ja)
KR (1) KR100822357B1 (ja)
CN (1) CN1304047C (ja)
AT (1) ATE322906T1 (ja)
AU (2) AU2002222513B8 (ja)
BR (1) BR0115190A (ja)
CA (1) CA2428176C (ja)
CY (1) CY1106092T1 (ja)
CZ (1) CZ299673B6 (ja)
DE (1) DE60118769T2 (ja)
DK (1) DK1331940T3 (ja)
ES (1) ES2261515T3 (ja)
HK (1) HK1061209A1 (ja)
HU (1) HU229100B1 (ja)
IT (1) IT1317930B1 (ja)
MX (1) MXPA03004005A (ja)
PL (1) PL205925B1 (ja)
PT (1) PT1331940E (ja)
SK (1) SK287791B6 (ja)
WO (1) WO2002038169A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
JP4667372B2 (ja) * 2004-02-25 2011-04-13 株式会社ペルセウスプロテオミクス 血管障害の程度の判定方法
ITRM20040489A1 (it) 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
BRPI0707239A8 (pt) 2006-01-24 2018-01-30 Sigma Tau Ind Farmaceuti peptídeo de ligação de fgf2, peptídeo quimérico fundido ou conjugado, molécula de ácido nucléico, vetor de expressão, célula hospedeira e composição farmacêutica
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
BRPI0711136A2 (pt) 2006-05-02 2011-08-30 Sigma Tau Ind Farmaceuti uso de timosina alfa1, isoladamente ou em combinação com ptx3 ou ganciclovir, para o tratamento de infeção por citomegalovìrus
US20150299277A1 (en) * 2012-06-22 2015-10-22 The University Of Tokyo Agent for treating or preventing systemic inflammatory response syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012176A1 (en) * 1991-01-14 1992-07-23 New York University Cytokine-induced protein, tsg-14, dna coding therefor and uses thereof
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,

Similar Documents

Publication Publication Date Title
BE2022C531I2 (ja)
BE2022C502I2 (ja)
BE2022C547I2 (ja)
BE2017C056I2 (ja)
BE2017C051I2 (ja)
BE2017C032I2 (ja)
BE2016C051I2 (ja)
BE2015C046I2 (ja)
BE2014C052I2 (ja)
BE2014C036I2 (ja)
BE2014C026I2 (ja)
BE2014C004I2 (ja)
BE2017C050I2 (ja)
BE2011C034I2 (ja)
AU2002307149A8 (ja)
JP2002165789A5 (ja)
JP2002245775A5 (ja)
BRPI0209186B1 (ja)
BE2014C008I2 (ja)
BRPI0204884B1 (ja)
CH1379220H1 (ja)
BE2017C059I2 (ja)
JP2002033680A5 (ja)
JP2001224588A5 (ja)
HU0202369D0 (ja)